New York, NYNCT07491497Now EnrollingIRB Ready

ALK-positive NSCLC Clinical Trial in New York, NY

Access cutting-edge alk-positive nsclc treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by TRIANA Biomedicines, Inc.

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access alk-positive nsclc specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related alk-positive nsclc treatment provided free

Apply for This New York Location

Check if you qualify for this alk-positive nsclc clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This ALK-positive NSCLC Study in New York

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: * Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not progressing * Visit the clinic approximately seven times in the first 3 months and then just once at the start of each 28-day cycle thereafter * Keep a diary of each time they take the study medication

Sponsor: TRIANA Biomedicines, Inc.

Who Can Participate

Inclusion Criteria

Pathologically confirmed diagnosis of ALK-positive non-small cell lung cancer (NSCLC)
Measurable disease per RECIST v1.1
Adequate bone marrow reserve and organ function
Part 1: prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line
Part 2 Cohort M1: prior treatment with 2 to 3 ALK TKIs, prior treatment with lorlatinib is required but must not have been in the first line, prior treatment with neladalkib is excluded
Part 2 Cohort M2: prior treatment with more than 3 ALK TKIs, prior treatment with lorlatinib and neladalkib is required but neither may have been in the first line
Part 2 Cohort M3: participants without prior ALK TKI treatment

Exclusion Criteria

Participant's cancer has any additional driver alterations known to be a mechanism of resistance to ALK TKIs
For participants with central nervous system (CNS) metastases or spinal cord compression, they must not be associated with progressive neurological symptoms or require increasing doses of corticosteroids to control the CNS disease
Ongoing treatment with another anticancer treatment or investigational agent
Known allergy/hypersensitivity to TRI-611 or any of its ingredients
Major surgery within 4 weeks of receiving the first dose of TRI-611

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07491497) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

ALK-positive NSCLC Treatment Options in New York, NY

If you're searching for alk-positive nsclc treatment options in New York, NY, this clinical trial (NCT07491497) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alk-positive nsclc specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alk-positive nsclc clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in New York, NY

See all lung cancer clinical trials recruiting in New York — not just this study.

Browse Lung Cancer Trials in New York →

Browse More Trials by Condition

Lung Cancer TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY